Improving outcomes in testicular cancer survivorship requires a deep understanding of long-term mortality risks. While testicular germ cell tumors (GCTs) are highly curable in adolescent and young adult (AYA) males, survivors face significant health challenges decades after their primary treatment. A recent population-based analysis using SEER data provides critical insights into what causes death in this population and when these risks emerge.

Mortality Drivers in Testicular Cancer Survivorship

The study analyzed 1,870 deaths among AYA survivors, revealing that primary GCT remains the leading cause of mortality, accounting for 52% of deaths. However, non-testis cancers and non-cancer causes represent a substantial portion of the mortality burden. Specifically, secondary malignancies contributed to 15% of deaths, showing a standardized mortality ratio (SMR) of 4.13. This indicates that AYA survivors are over four times more likely to die from secondary cancers compared to the general population.

Furthermore, non-cancer causes accounted for 32% of total deaths. Notably, researchers observed higher-than-expected mortality rates for chronic liver disease and cirrhosis. Surprisingly, heart disease mortality was lower than expected in this cohort. Histology also played a role; for instance, non-seminoma was associated with higher GCT mortality and a modest elevation in deaths related to diabetes and liver disease.

Time-Dependent and Stage-Specific Risks

Risk profiles in testicular cancer survivorship shift dramatically based on the stage at diagnosis and the time elapsed since treatment. Stage I patients most frequently succumbed to external causes, such as accidents, suicide, or homicide. Conversely, patients diagnosed with Stage III disease experienced markedly elevated mortality from secondary cancers. These findings suggest that the intensity of initial treatment, which often correlates with stage, significantly influences long-term health outcomes.

Timing is another crucial factor. During the first five years post-diagnosis, GCT-specific deaths and behavioral health-related deaths (accidents and suicide) predominate. In contrast, after ten years, non-cancer deaths become the primary cause of mortality. Consequently, survivorship care must evolve from intensive oncological surveillance to comprehensive health monitoring that includes behavioral health support and secondary cancer screening.

Practical Implications for Clinicians

Clinicians should prioritize a multidisciplinary approach to long-term follow-up. Since AYA survivors face elevated risks of liver disease and secondary malignancies, regular screenings and lifestyle interventions are essential. Moreover, the prevalence of early deaths from suicide and accidents underscores the need for robust behavioral health integration within oncology programs. Therefore, survivors require a tailored care plan that addresses both physical and psychological late effects of cancer therapy.

Frequently Asked Questions

What are the primary non-cancer causes of death in testicular cancer survivors?

The leading non-cancer causes include chronic liver disease, cirrhosis, and behavioral health issues such as accidents and suicide. While cardiovascular risks are often a concern in cancer survivors, this specific study found heart disease mortality to be lower than expected in the AYA cohort.

How does the risk of secondary cancer change over time?

Secondary cancer mortality risk is particularly elevated in patients who had advanced-stage (Stage III) disease. While GCT deaths are most common in the first five years, secondary malignancy and other non-cancer risks become the dominant concerns after ten years of survivorship.

Does histology affect long-term survival?

Yes. Non-seminoma histology is associated with higher primary GCT mortality. It is also linked to a modest increase in mortality from metabolic and hepatic conditions, such as diabetes and chronic liver disease.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Toumazos K et al. Survivorship after Testicular Cancer in Adolescents and Young Adults- What is Causing Death and When? J Urol. 2026 Apr 28. doi: 10.1097/JU.0000000000005101. PMID: 42048675.

Hellesnes R, et al. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. J Clin Oncol. 2022;40(12):1334-1346.

American Cancer Society. Testicular Cancer Survival Rates. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026.